NCT02827903 is a Phase 3 clinical trial of Metformin + Rosuvastatin in Type 2 Diabetes, sponsored by Jeil Pharmaceutical Co., Ltd..

Who is sponsoring NCT02827903?

NCT02827903 is sponsored by Jeil Pharmaceutical Co., Ltd..

What drugs are being tested in NCT02827903?

Interventions in NCT02827903: Metformin + Rosuvastatin, Metformin + placebo, placebo + Rosuvastatin.

What condition does NCT02827903 study?

NCT02827903 studies Type 2 Diabetes, Dyslipidemia.

Is NCT02827903 still recruiting?

NCT02827903 is currently completed. Last updated 6 July 2018.

Last reviewed 2018-07-06 · How we verify

NCT02827903

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia

Completed Phase 3 Last updated 6 July 2018

What this trial tests

Phase 3 trial testing Metformin + Rosuvastatin in Type 2 Diabetes in 237 participants. Completed in 16 March 2018.

Timeline

15 January 2016

Primary endpoint
21 November 2017

16 March 2018

Quick facts

Lead sponsor	Jeil Pharmaceutical Co., Ltd.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	237
Start date	15 January 2016
Primary completion	21 November 2017
Estimated completion	16 March 2018
Sites	33 locations across South Korea

Drugs / interventions tested

Metformin + Rosuvastatin — full drug profile →
Metformin + placebo — full drug profile →
placebo + Rosuvastatin — full drug profile →

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →
Dyslipidemia — all drugs for Dyslipidemia →

Sponsor

Jeil Pharmaceutical Co., Ltd. — full company profile →

Who can join

19 and older, any sex, with Type 2 Diabetes or Dyslipidemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Compare the Efficacy and Safety of Metformin/Rosuvastatin Combination Therapy With Metformin or Rosuvastatin Monotherapy in Patients With Type 2 Diabetes and Dyslipidemia

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Metformin + Rosuvastatin

Trials testing the same drug.

NCT02982798 — The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers · Phase 1 · completed

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other Jeil Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07115706 — JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD · not yet recruiting
NCT06952855 — Observationa Study is a Prospective and Multi-institutional Observational Study. · completed
NCT06431399 — To Evaluate the Safety, Pharmacokinetic Characteristics and the Effect of Food After Administration of JLP-2004 · Phase 1 · recruiting
NCT06169059 — To Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004 · Phase 1 · completed
NCT06165965 — To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008 · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02827903 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jeil Pharmaceutical Co., Ltd.
Last refreshed: 6 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02827903.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing